Počet záznamů: 1  

Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF

  1. 1.
    0191680 - UMG-J 20033195 RIV GR eng J - Článek v odborném periodiku
    Mikyšková, Romana - Indrová, Marie - Šímová, Jana - Jandlová, Táňa - Bieblová, Jana - Jinoch, P. - Bubeník, Jan - Vonka, V.
    Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF.
    International Journal of Oncology. Roč. 24, č. 1 (2004), s. 161-167. ISSN 1019-6439
    Grant CEP: GA MZd NC7148; GA MZd NC7552; GA ČR GA301/01/0985
    Výzkumný záměr: CEZ:AV0Z5052915
    Klíčová slova: HPV16 * gene therapy * minimal residual tumour disease
    Kód oboru RIV: FD - Onkologie a hematologie
    Impakt faktor: 3.056, rok: 2004

    Moderately immunogenic HPV16-associated tumours, MHC class I positive as well as negative, were used to examine the effects of local IL-2 and GM-CSF cytokine or gene therapy in the treatment of minimal residual tumour disease induced surgically or chemotherapeutically. Both types of neoplasms were found to be inhibited with adjuvant cytokine therapy. It is of interest to further investigate whether this is a general phenomenon in HPV16-associated tumour systems.
    Trvalý link: http://hdl.handle.net/11104/0087418
     

Počet záznamů: 1